Background And Objectives: High rates of recurrence have been observed after curative treatment for hepatocellular carcinoma (HCC). The main aim of this study was to establish the influence of adjuvant transarterial radioembolization-based I-131 lipiodol on survival and recurrence.
Methods: Between 2004 and 2010, 38 patients were treated with adjuvant I-131 lipiodol therapy, at a dosage of 2220 MBq, within 4 months after surgery. This treated cohort was compared to a control cohort consisting of 42 consecutive patients operated prior to the time the I-131 lipiodol treatment became available.
Results: Recurrence-free survival in the control and in the I-131 lipiodol cohort was 12.6 and 18.7 months, respectively (HR = 1.871, p = 0.025). At 2 and 5 years, the cumulative incidence of a first recurrence or death was, respectively, 50 % and 61 % in the treated cohort versus 69 % and 74 % in the control cohort. Median overall survival was 55 and 29 months, respectively (p = 0.051). Among patients with a recurrence at 2 years, more patients had already experienced such recurrence at 1 year in the control cohort (70 % vs 33 %, p = 0.014).
Conclusions: Adjuvant I-131 lipiodol improves disease-free survival in patients with HCC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00268-016-3502-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The inhibiting effect of alpha-based TARE on embolized vessels and neovascularization.
Front Bioeng Biotechnol
October 2022
Department of Nuclear Medicine, Changhai Hospital, Naval Medical University, Shanghai, China.
Transarterial embolization (TAE) is a personalized technology that offers precise delivery of chemotherapeutic drugs or selective internal radiation therapy for hepatocellular carcinoma (HCC). Beta-emitting radionuclide embolisms for TAE (β-based TARE) are commonly used in the clinic inducing biochemical lethality on tumor cells, while alpha-emitting radionuclides-based embolisms for TAE (α-based TARE) are still under study. The feeding artery plays a key role in tumor growth, metastasis, and recurrence.
View Article and Find Full Text PDFAdjuvant I-131 Lipiodol After Resection or Radiofrequency Ablation for Hepatocellular Carcinoma.
World J Surg
August 2016
Department of Digestive Surgery, Rouen University Hospital-Charles Nicolle, Rouen, France.
Background And Objectives: High rates of recurrence have been observed after curative treatment for hepatocellular carcinoma (HCC). The main aim of this study was to establish the influence of adjuvant transarterial radioembolization-based I-131 lipiodol on survival and recurrence.
Methods: Between 2004 and 2010, 38 patients were treated with adjuvant I-131 lipiodol therapy, at a dosage of 2220 MBq, within 4 months after surgery.
Adjuvant Iodine (131) Lipiodol after Resection of Hepatocellular Carcinoma.
J Oncol
December 2015
Department of Surgery, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW 2050, Australia.
Background. Survival after liver resection for HCC is compromised by a high rate of intrahepatic recurrence. Adjuvant treatment with a single, postoperative dose of intra-arterial I(131) lipiodol has shown promise, as a means of prolonging disease-free survival (DFS).
View Article and Find Full Text PDFSystematic review and meta-analysis of adjuvant i(131) lipiodol after excision of hepatocellular carcinoma.
Ann Surg Oncol
August 2014
Upper Gastrointestinal Surgery and Transplant unit, Royal Prince Alfred Hospital, Camperdown, NSW, Australia,
Background: Curative resection for hepatocellular carcinoma (HCC) has an 80 % recurrence at 5 years. Survival could be prolonged with adjuvant iodine(131) lipiodol. This systematic review and meta-analysis was designed to assess the survival benefit of this treatment in patients with resected HCC compared with surgery alone.
View Article and Find Full Text PDFAdjuvant lipiodol I-131 after curative resection/ablation of hepatocellular carcinoma.
HPB (Oxford)
May 2010
University of New South Wales, Department of Surgery, St. George Hospital, Sydney, New South Wales, Australia.
Aim: A total of 329 patients with hepatocellular carcinoma have been treated at our unit since 1990. Following the randomized controlled trial in Hong Kong by Lau et al. in 1999, patients have been offered adjuvant lipiodol I-131.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!